Skip to content

Prevention of Diverticulitis by Taking a Daily Probiotic

Does a Daily Dose of the Probiotic Lactobacillus Casei Shirota Prevent Acute Episodes of Diverticulitis (LACTOPRoD) - a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01609751
Acronym
LACTOPRoD
Enrollment
26
Registered
2012-06-01
Start date
2013-04-30
Completion date
2015-01-31
Last updated
2016-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Diverticulitis

Keywords

probiotic, lactobacillus, colonic diseases, dietary fibre

Brief summary

There is evidence to show that daily probiotic Lactobacillus casei Shirota (LcS) in the form of Yakult fermented milk supports a healthy balanced population of friendly gut bacteria. This, coupled with evidence from four European trials showing probiotic benefit for recurrent diverticulitis and an understanding of how the disease develops, indicates that LcS may also be beneficial. The investigators plan to undertake a pilot study investigating whether consumption of once daily probiotic LcS as Yakult fermented milk would help either prevent attacks of diverticulitis completely or significantly reduce frequency of attacks. Subjects will be recruited from Surrey primary care units and will be closely monitored for 12 months whilst being supplied with a daily dose of for the full 12 months to see if this improves gut health.

Detailed description

Because dietary fibre, obesity and diabetes are all confounding factors that influence the frequency and severity of attacks of diverticulitis, the research project will take account of this by: 1. Monitoring dietary fibre using a diet diary 2. Measurement of height and weight to determine BMI 3. Screening for undiagnosed diabetes and pre-diabetes As well as keeping a diet diary, subjects will be asked to keep a general health diary, and to complete gut health questionnaires at start, 6 months and 12 months.

Interventions

DIETARY_SUPPLEMENTYakult

62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.

Sponsors

University of Surrey
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. A history of two episodes of UAD treated with antibiotics in the last five years. 2. Diverticulosis confirmed by colonoscopy, barium enema, USS, CT or MRI imaging or at surgery. 3. Agreement to consume one bottle of Yakult daily for 12 months 4. Availability of space in the domestic refrigerator for storage of Yakult units 5. Able to access depot (local primary care premises or chemist) to collect regular supplies of Yakult 6. Able to cope with keeping a diary etc. 7. Willing to take Yakult supplies and a cold bag on holiday to ensure as near as possible continuous daily doses (certainly never more than one week break as Lactobacilli casei will persist in the human gut for at least one week 8. Capable of giving informed consent 9. Aged ≥ 50 and ≤ 75 years at commencement of trial.

Exclusion criteria

1. Recent history of peptic ulcer 2. Chronic renal insufficiency 3. Ongoing or past major diverticulitis complications 4. Any serious debilitating illness (cancers, cardiovascular disease etc. but not DM) 5. Dementias or memory problems 6. Regular probiotic consumption over the past year. 7. Undergoing immunosuppressive therapy or treatment 8. Lactose intolerance or intolerance to dairy products 9. Immunosuppressed patients

Design outcomes

Primary

MeasureTime frameDescription
Number of episodes of acute diverticulitis12 months period of taking daily probioticAn episode of diverticulitis will be judged as having occured when there is left iliac pain and tenderness judged by the patient's genral practitioner to be due to acute diverticulitis and to be sufficiently severe as to require a course of antibiotics

Secondary

MeasureTime frameDescription
Gut symptoms assessed by a validated questionnaire at o months, 6 months and 12 months12 monthsThe Bovenschen GIT symptom questionnaire (Bovenschen HJ, Janssen MJR, van Oijen MGH, Laheij RJF, van Rossum LGM, Jansen JBMJ (2006).Evaluation of Gastrolintestinal symptoms questionnaire. Digestive Diseases and Science;51:1509-1515.) will be used to assess this secondary endpoint

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026